US Patent Issued to GlaxoSmithKline Intellectual Property (No.3) on May 26 for "Crystalline forms of a substituted imidazopyridine compound and use thereof as P2X3 modulator" (Canadian Inventors)

ALEXANDRIA, Va., May 26 -- United States Patent no. 12,637,452, issued on May 26, was assigned to GlaxoSmithKline Intellectual Property (No.3) Ltd. (Stevenage, Great Britain).

"Crystalline forms of a substituted imidazopyridine compound and use thereof as P2X3 modulator" was invented by Denis Garceau (Laval, Canada), Robert M. Wenslow Jr. (Laval, Canada), Kemal Payza (Laval, Canada) and Nathalie Chauret (Laval, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are crystalline forms of a P2X3 modulator, namely (S)-methyl-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate or a solvate thereof, and use thereof for treating pain, ...